Pharmaceutical manufacturers of Dexamethasone

Pfizer CentreOne® is a completely distinct global contract development and manufacturing organization (CDMO), as well as a prominent provider of specialty APIs and intermediates. Supported by resources from Pfizer, we have provided technical knowledge, regulatory assistance, and long-term supply for more than 40 years. With a network of over 35 sites spanning six continents, we are capable of securely and effectively guiding complex compounds from development to commercial manufacture. For more details, please visit http://www.pfizercentreone.com

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

Euroapi focuses on revolutionizing active component solutions to sustainably fulfill the demands of clients and patients globally. As a prominent figure in active pharmaceutical ingredients, we possess a comprehensive portfolio of around 200 products, encompassing a wide range of technologies, and are constantly developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO). Our 3,350 employees are driven by the commitment to improving access to essential therapies and promoting health

Our objective is to pave the path to a more wholesome future. However, we are also concerned about the manner in which we collectively achieve this goal. Being a company whose products impact the well-being of individuals worldwide, we uphold ourselves to a stringent standard and anticipate others to treat us likewise. We are advocates of transparent, truthful, and principled operation with the utmost level of ethics and honesty. This encompasses ensuring the company's compliance with all relevant laws and regulations on a global scale.

Formed through the fusion of Farmabios, Novasep, and PharmaZell, Axplora stands out as a principal manufacturer of active pharmaceutical ingredients (APIs), ensuring the timely and scalable delivery of high-quality compounds. With a collective proficiency and a diverse production capacity spanning 9 industrial facilities, incorporating specialized technologies such as Hazardous Chemistry, Chromatography, ADCs, Steroids, Continuous Processes, Lipids, and HPAPIs, Axplora provides dependable and flexible solutions: CDMO services for small molecule APIs and biopharmaceuticals to both innovators and generic API Products. We, at Axplora, are committed to unifying Farmabios, Novasep, and PharmaZell, establishing ourselves as a top-tier API manufacturer dedicated to serving the foremost patient-focused pharmaceutical and biotechnology enterprises, ensuring the reliable and sustainable production of premium active ingredients in adherence to the highest industry standards. Axplora's mission is centered on empowering pharmaceutical companies to enhance the development of vital medications, fostering a faster, safer, and more dependable approach to benefit patients worldwide. Leveraging our combined expertise and manufacturing facilities spread across nine sites in Europe and India, along with a research and development center in the USA, Axplora is positioned to offer comprehensive CDMO solutions.

Symbiotec Pharmalab Pvt. Ltd is a prominent manufacturer of Active Pharmaceutical Ingredients (APIs) for Cortico Steroids and Sex Hormones, serving over 35 markets, including North America, Europe, Israel, and Japan. Established in 1995 in Central India, the company holds accreditations from US-FDA, EU-GMP, and WHO-GMP. It has received eighteen (18) Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs) from the European Directorate for the Quality of Medicines (EDQM) and has filed several Drug Master Files (DMFs) with EDQM and FDA. Symbiotec is dedicated to providing cGMP compliant material with comprehensive regulatory support, coupled with the advantage of lower production costs in Asia. The company offers Lyophilized Sterile and Micronized Steroids and Hormones with a particle size of up to 5 microns. For a complete range of products and further details, please visit their website.

Founded as Xianju Pharmacy Plant in 1972, Xianju Pharmaceutical Co., Ltd. (stock code: 002332) practices the corporate philosophy of “ your health and happiness, my sincerity and service” and focuses on steroid hormones with the vision of “ Becoming the one of the Top 10 steroid hormone suppliers in the world and a business well-received among customers and employees.” It has a total capital stock of 989.204866 million yuan and more than 3600 employees. As a key high-tech enterprise of the National Torch Plan, the company ranked 67th among the top 100 in the Chinese pharmaceutical industry in 2020 with a provincial steroid medicine engineering technology research center in Zhejiang Province and a national post-doctoral center. As the only company holding fast to the business pattern integrating bulk pharmaceutical chemicals and preparations, the company specializes in the research, production and sale of bulk pharmaceutical chemicals and steroid preparations. In its product development, the company sticks to the four major fields of health care (gynecology, anesthesiology, respiratory medicine, and dermatology) to build mixes of products and services. The company has established long-term partnership with more than 20 domestic prestigious research institutes and universities including the Shanghai institute of Organic Chemistry, Chinese Academy of Sciences, Zhejiang University and China Pharmaceutical University to bring in senior researchers and gradually align with the new drug development in the world. The company has formed a technical framework that originates from overseas high-end research institutions, assimilates through the research institutions in Hangzhou and Xianju and Implements them with the base in Xianju. Under the company, there are 20 wholly-owned and holding subsidiaries such as time Xianju Pharmaceutical Co., Ltd. The company has three core manufacturing platforms, which are Xianju Yangfu bulk pharmaceutical chemicals production zone, Xianju Yangfu preparation production zone and Linhai Yangfu productions zone at home and two standard bulk pharmaceutical chemicals plants under the name of NewChem, its subsidiary in Italy. Xianju Pharma advocates the culture celebrating authenticity, win-win results and innovation and core values of honesty, hard work, openness, studiousness, responsibility and mutual benefit. Upholding the strategic objective of achieving win-win results with customers, enterprises, employees and communities, the company promotes the values that individuals’ value is reflected when they benefit their communities and companies. In its future development, the company will continue optimizing its business management, developing high-tech products and leverage on its large business size to achieve high-quality development and make contributions to the health care of mankind.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Società Italiana Medicinali Scandicci, known as S.I.M.S. srl, was established in Scandicci in 1937 by Mr Ugo Rangoni. During the 1950s and 1960s, it experienced growth in both production and personnel. In 1972, the first DMF (phenylbutazone) was presented to the FDA. The current API facility in Reggello has been operational since 1974 and has been regularly examined by the Agency ever since. Since the 1980s, the company has garnered increasing recognition in the field of custom-toll manufacturing through GMP status with major partners. The company has more than 20 APIs with registered DMF and, when applicable, the corresponding CEP.

TIANJIN PHARMACEUTICAL HOLDINGS CO., LTD. advocates the corporate core values of "Love, Integrity and Power", and has been working to improve people's health and well-being, protect people's lives, benefit the public and safeguard people's happy life, and is committed to building a market-driven, technology-empowered leader in the health industry.

STERIS Applied Sterilization Technologies offers sterilization services, laboratory testing, and product and packaging testing to companies in the medical device and pharmaceutical industries.

Anuh Pharma Ltd., a Bulk Drugs Manufacturing Company is part of the INR 8.5 bn SK Group of Companies, which employs 2000+ people across businesses such as Manufacturing of API's, Pharma Formulations, Distribution and Logistics. Established in 1960, Anuh Pharma Ltd. today is one of the largest manufacturers of Macrolides and Anti-TB products in India, besides being a major player in Anti-Bacterials, Anti-Malarial, and Corticosteroids.

Established in the year 1991, SM Biomed Sdn. Bhd. is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates based out in Malaysia With our state-of-the-art manufacturing facility certified by USFDA, EDQM, EUGMP and NPRA (Malaysia), we are dedicated to improve the quality of life through developing and delivering innovative solutions and products at an affordable cost. With a legacy spanning more than three decades and pioneers for Macrolide based antibiotics, we work with customers globally with speed, efficiency and cost effective manufacturing capabilities. SM Biomed has grown as a market leader in Macrolides antibiotics and evolved into a knowledge driven company providing reliable pharmaceutical services including developing and manufacturing APIs and Intermediates. From pipeline to production, we make innovative, quality driven and customised products more accessible. We are a quality driven and R&D focused API manufacturing company with a diverse product portfolio catering various therapeutic segments.

Symbiotica produces active pharmaceutical ingredients at their cGMP Facility certified as ICHQ7, PIC/S GMP, successfully examined by the USFDA, COFEPRIS & PMDA. Regularly reviewed by clients including MNC's. Facilities comprise of Dedicated Steroidal & Specialized Non-steroidal blocks. A new Sterile-Steroidal facility is being established at a new location. We possess 11 CEP's & 8 USDMF's

Vamsi Labs, founded in 1991, is a prominent Indian producer of active pharmaceutical ingredients (API). It specializes in anti-asthmatic, anti-migraine, and anti-psychotic APIs, serving both domestic and international markets with 50% sales contribution from the latter. Sales of anti-asthma products make up 60% of the total sales. Vamsi upholds stringent corporate governance, transparency, professionalism, and environmental conservation standards. The company is approved by USFDA and holds certifications for ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018. It also features a DSIR-certified R&D Lab, allowing Vamsi to continue innovating to meet the evolving requirements of the pharmaceutical industry. Vamsi is positioned for global expansion while maintaining its dedication to excellence and sustainability.

Hameln rds s.r.o. is situated in Slovakia, a member of the European Union, in the region of Europe. It is a reputable pharmaceutical company that specializes in producing APIs and providing services for the healthcare sector, focusing on various stages of pharmaceutical product development and production, encompassing analytical and galenical development. Hameln offers a broad spectrum of services, including QC services (such as stabilities and batch release) and the development and manufacturing of APIs. Serving as a centralized API production facility, supply and trading chain, as well as a hub for research and development, Hameln rds plays a pivotal role in the pharmaceutical industry.